Resistance of corneal RFUVA-cross-linked collagens and small leucine-rich proteoglycans to degradation by matrix metalloproteinases by Zhang, Yuntao et al.
Cornea
Resistance of Corneal RFUVA–Cross-Linked Collagens and
Small Leucine-Rich Proteoglycans to Degradation by
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PURPOSE. Extracellular matrix metalloproteinases (MMPs) are
thought to play a crucial role in corneal degradation associated
with the pathological progression of keratoconus. Currently,
corneal cross-linking by riboflavin and ultraviolet A (RFUVA)
has received significant attention for treatment of keratoconus.
However, the extent to which MMPs digest cross-linked
collagen and small leucine-rich proteoglycans (SLRPs) remains
unknown. In this study, the resistance of RFUVA–cross-linked
collagens and SLRPs to MMPs has been investigated.
METHODS. To investigate the ability of MMPs to digest cross-
linked collagen and SLRPs, a model reaction system using
purified collagen type I, type IV, and nonglycosylated,
commercially available recombinant SLRPs, keratocan, lumi-
can, mimecan, decorin, and biglycan in solution in vitro has
been compared using reactions inside an intact bovine cornea,
ex vivo.
RESULTS. Our data demonstrate that corneal cross-linked
collagen type I and type IV are resistant to cleavage by MMP-
1, MMP-2, MMP-9, and MMP-13, whereas non–cross–linked
collagen I, IV, and natively glycosylated SLRPs are susceptible
to degradation by MMPs. In addition, both cross-linked SLRPs
themselves and cross-linked polymers of SLRPs and collagen
appear able to resist degradation. These results suggest that the
interactions between SLRPs and collagen caused by RFUVA
protect both SLRPs and collagen fibrils from cleavage by MMPs.
CONCLUSIONS. A novel approach for understanding the bio-
chemical mechanism whereby RFUVA cross-linking stops
keratoconus progression has been achieved. (Invest Ophthal-
mol Vis Sci. 2013;54:1014–1025) DOI:10.1167/iovs.12-11277
Keratoconus is a bilateral noninflammatory corneal ectasia,typically characterized by three histopathological signs:
progressive corneal thinning, Bowman’s layer breakage, and
iron deposits in the basal layer of the corneal epithelium.1,2
Keratoconus is detected when the normally spherical cornea
begins to bulge outward acutely. This abnormal shape usually
occurs as the central stromal region becomes thinner,
preventing light from entering the eye and being focused
correctly on the retina and causing distortion of vision.3
Keratoconus may progress for 10 to 20 years and then slow
down, and each eye may be affected differently. Keratoconus
affects 1 in 2000 people2 and was the leading indicator for
penetrating keratoplasty in 2011 and 2010.4
The stroma comprises approximately 90% of the corneal
thickness in humans.5 Collagen gives the cornea its strength,
elasticity, and form.6 The unique molecular shape, paracrystal-
line arrangement, and very fine diameter of the evenly spaced
collagen fibrils are essential in producing a transparent
cornea.7,8 Corneal stroma is composed primarily of orthogonal
plies/lamellae of collagen fibrils, each of which consists of a
core of type V collagen coated with type I collagen,9,10 coated
in turn by two classes of proteoglycans (PGs),11 of which
keratan sulfate PGs (KSPGs) are the predominant class.
Through N-linked oligosaccharides, KS glycosaminoglycan
(GAG) chains are attached covalently to three core proteins:
lumican (LUM), keratocan (KER), and mimecan (MIM) to form
KSPGs.12–14 These three core proteins belong to a class of
proteins known as small leucine-rich repeat proteins
(SLRPs).15–17 The other major class of PGs in corneal stroma
is modified with chains of chondroitin/dermatan sulfate (CS/
DS). Through O-linked oligosaccharide, CS/DS GAG chains are
attached to the core SLRPs decorin (DCN)18,19 and biglycan
(BGN).20,21 In the case of DCN, a single CS/DS linkage site is
present near the amino terminus of the core protein, whereas
BGN possesses two potential CS/DS linkage sites.20,21 For LUM
and KER, there are four or five potential KS attachment sites in
their central leucine-rich repeat regions,12,22,23 and MIM has
two potential KS attachment sites.24,25
The most important clinical feature of keratoconus is
thinning and ectasia of the cornea, suggesting that degradation
of the stromal extracellular matrix may occur during the
progression of keratoconus. In the stroma, a decrease in the
number of lamellae and keratocytes,26 changes in the gross
organization of the lamellae, and uneven distribution of
collagen fibrillar mass and inter- and intralamellae, particularly
around the apex of the cone, have been observed.27
Degradative extracellular enzymes, such as matrix metal-
loproteinases (MMPs), may play crucial roles in corneal
degradation associated with keratoconus.28–31 MMPs are a
large family of calcium-dependent zinc-containing endopepti-
dases, which are responsible for tissue remodeling and
degradation of the extracellular matrix (ECM), including
collagens, elastins, gelatin, matrix glycoproteins, and
PGs.32,33 Under normal physiological conditions, MMPs are
minimally expressed and homeostasis is maintained. The
cornea is 70% collagen by weight, and the reduced collagen
content of the keratoconic cornea suggests a degraded
extracellular matrix.27 Early studies detected increased MMP
activities in keratoconus corneas, especially MMP-1, -2, -9, and
-13.34–38 MMPs are inhibited by tissue inhibitors of MMP
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(TIMPs) which comprise a family of four protease inhibitors,
TIMP-1, -2, -3, and -4.39 Thus, MMPs are widely assumed to
have a central role in the pathogenesis of keratoconus.
Recently, a new technique for corneal cross-linking was
devised that directly improves the biomechanical rigidity of the
corneal stroma. This approach consists of irradiation of the
cornea with ultraviolet A (UVA) in the presence of the
photosensitizer riboflavin (RF), as a chromophore.40,41 Cross-
linking RFUVA treatment effectively stops the progression of
the keratoconus syndrome, although the mechanism is not
clear and remains under study. Our recent work demonstrated
that RFUVA treatment causes cross-linking of collagen mole-
cules among themselves and of PG core proteins among
themselves, together with limited linkages between collagen
and KER, LUM, MIM, and DCN.42 However, the mechanism
whereby RFUVA cross-linking stops the degradation processes
associated with keratoconus has not been elucidated. In this
study, a model reaction system using purified collagens and
nonglycosylated, commercially available recombinant SLRPs in
solution in vitro has been compared with reactions inside an
intact cornea, ex vivo, revealing that RFUVA causes resistance
of corneal cross-linked collagens and small leucine-rich PGs to
degradation by MMPs.
MATERIALS AND METHODS
Materials
Bovine eyeballs were freshly collected from Alta Vista Locker (Alta
Vista, KS). Collagen type I from bovine skin was purchased from
Inamed (Fremont, CA). All animals were used in accordance with the
ARVO Statement for the Use of Animals for Ophthalmic and Vision
Research. Collagen type IV from human placenta, 50-monophosphate
sodium salt RF and CS56 antibody were purchased from Sigma (St.
Louis, MO). Anti-KS antibody J36 was kindly provided by Nirmala
SundarRaj (University of Pittsburgh). Recombinant human MMPs,
recombinant human LUM, recombinant mouse MIM, recombinant
human DCN, recombinant human BGN proteins, anti-human LUM
antibody, anti-mouse MIM antibody, anti-human DCN antibody, and
anti-human BGN antibody were purchased from R&D Systems
(Minneapolis, MN). Recombinant human KER and anti-KER polyclonal
antibodies were purchased from Abnova Corp. (Taipei, Taiwan). Rabbit
polyclonal antibody to collagen type I (code ab34710) was purchased
from Abcam Inc. (Cambridge, MA). NuPAGE Novex tris-acetate precast
gels and chromogenic Western blotting kits were purchased from
Invitrogen Corp. (Carlsbad, CA).
Analysis of Amino Acids
Twenty-microliter volumes containing 1 lg/lL collagen and 0.1% RF
(in phosphate-buffered saline [PBS]) in 0.5-mL plastic centrifugation
tubes were irradiated with 370 nm of UVA light for 30 minutes at a
distance of 5 cm from the light source at room temperature. The
sample solution was irradiated with the UVA light shining directly
onto the surface of the solutions, mixed twice by vortexing at 10-
minute intervals while it was being irradiated. Prior to being
hydrolyzed, the residual RF was not removed from the samples.
Amino acids were analyzed by the AAA Service Laboratory
(Damascus, OR). Briefly, 10 nM of norleucine as an internal standard
was added to 20 lL of each sample. Samples were hydrolyzed at
1108C for 22 hours in 1 mL of 6N-HCl with 2% phenol under vacuum.
After hydrolysis, samples were dried and then resuspended in 100 lL
of sample buffer, of which 50 lL was injected into an amino acid
analyzer (model L8900; Hitachi, Tokyo, Japan), and analysis was
performed using post-column ninhydrin derivatization. Molar ratio
(%) was represented by the molar concentration of each amino acid
per total amino acids. Data are means 6 standard deviations (SD)
from three separate experiments.
MMPs Degradation System In Vitro
Soluble collagen type I was cross-linked by the photosensitizer RF and
UVA under conditions that resembled those used for RFUVA clinical
treatment of progressive keratoconus.42 Briefly, 15 lL of the mixture of
purified type I collagen (1 lg/lL in PBS) and RF (0.1% in PBS) was
irradiated with UVA of 370 nm for 30 minutes at a distance of 5 cm
from the light source (UV-X radiation system for corneal cross-linking;
Iroc Medical, Zurich, Switzerland). The volume of the reaction solution
was 20 lL in 0.5-mL plastic centrifugal tubes. After cross-linking
treatment, the cross-linked collagen was used as a substrate for
digestion by MMPs. A total of 25 lL of 100 mM Tris containing 30 mM
NaCl and 20 mM CaCl2 (pH 7.5) was added into the cross-linked
solution (note that addition of 1, 10, and 100 lM ZnCl2 did not increase
the activity of MMP-1 [data not shown]). Aliquots of MMP (200 ng/lL)
were added at a series of amounts of 40, 60, 80, and 100 ng,
respectively. A 2-lL aliquot of 25 mM p-aminophenylmercuric acetate
and water was added to produce a final reaction volume of 50 lL. The
reaction solution was mixed by vortexing and then incubated for 24
hours at 378C. Enzymatic digestions were terminated by heating for 10
min in boiling water, and then samples were lyophilized.
Sodium Dodecyl Sulfate-Polyacrylamide Gel
Electrophoresis
Briefly, 5 lL of NuPAGE LDS sample buffer (Invitrogen) and 2 lL of
NuPAGE reducing agent (Invitrogen) were added to each sample
solution, heated at 708C for 10 minutes, and then loaded onto NuPAGE
Novex Bis-Tris 4% to 12% gels (8 cm 3 8 cm 3 1.5 mm precast gel
[Invitrogen]) and subjected to electrophoresis (100 mA/gel for 60
minutes). After electrophoresis, gels were stained with 0.1% (w/v)
Coomassie Brilliant Blue R-250.
Cross-Linking Treatment of Intact Whole Corneas
Ex Vivo
The cross-linking procedure was performed as described previously.42
Briefly, bovine corneal epithelium was mechanically removed using a
blunt knife, and 0.1% (w/v) RF in PBS was applied to the exposed
stromal surface by drips for 30 minutes before irradiation and performed
every 5 minutes during irradiation. Corneas were irradiated with UVA of
370 nm for 30 minutes at a distance of 5 cm from the light source.
Guanidine-HCl Extraction of Corneal Tissue
De-epithelialized bovine corneas (0.6 g wet weight) treated or
untreated with RFUVA were frozen by liquid nitrogen, pulverized,
homogenized further in 4 M guanidine-HCl (GHCl) containing protease
inhibitors,43 and then incubated for 24 hours at 08C to 48C with gentle
agitation. Tissue residue was removed by centrifugation at 10,000g for
30 minutes, and the supernatant was retained as the extract. The tissue
residue pellet was re-extracted for a second 24 h with fresh 4 M GHCl
solution. The two extracts were combined, neutralized by addition of 1
M NaOH, and then applied to a centrifugal filter (regenerated cellulose,
3000-molecular weight [MW] cutoff; Amicon Ultra; Millipore, Billerica,
MA), centrifuged to desalt, and concentrated to 1/5 of the original
volume. Retentates that did not pass through the filter were collected
and evaluated for degree of collagen cross-linking and resistance to
degradation without any further processing. Total protein concentra-
tions of GHCl extraction samples were determined using a spectro-
photometer (NanoDrop ND-2000c; Thermo Scientific).
Evaluation of Resistance of Cross-Linked Collagen
to MMPs Ex Vivo
Antibodies to collagen types I and IV and to each of the PG core
proteins were used to compare the resistance of non–cross-linked
versus cross-linked collagen and PG core proteins to digestion with
MMPs. The sample (15 lg of protein) was treated with MMP
concentrations of 0.8, 1.2, 1.6, and 2.0 ng/lL for 24 hours at 378C,
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as described above. Enzymatic digestions were terminated by heating
for 10 min in boiling water and then samples were lyophilized. The
same proportions of each digested sample were subjected to 4% to 12%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and then to Western blotting analysis. The antibodies used here are
capable of detecting collagens I and IV and the SLRP core proteins.
RESULTS
For collagen type I, nontreated versus RFUVA–cross-linked
samples, as analyzed by SDS-PAGE and Coomassie Blue
staining, RFUVA causes (a) a1, a2, and b chains to almost
disappear; b) c chains to increase slightly in intensity; c)
protein staining at the base of the well to increase (Fig. 1A,
compare lane 2 vs. 3; Figs. 1B–D, compare lane 1 vs. 2). These
results support earlier studies that concluded that collagen
treated with RFUVA cross-linking forms higher-molecular-
weight polymers in response to irradiation with UVA in the
presence of RF,42,44 a process that simultaneously modifies
several specific amino acids (Table 1). Anterior corneal stroma
is the location of the major effects of RF plus UVA treatment,40
and the stromal fibrils are composed primarily of collagen type
I. This collagen type therefore was chosen for the following
experiments.
Results of amino acid analyses are presented in Table 1. In
the case of collagen type I, distinct decreases in molar
percentages of methionine, tyrosine, histidine, hydroxylysine,
and lysine in cross-linked collagen were observed compared to
their respective percentages detected in untreated collagen
type I, suggesting that these amino acids are significantly
modified by RFUVA. Similar results were detected with
collagen type IV (Table 1).
As can be seen in Figure 1A, using the current reaction
conditions, incubation of samples of purified collagen type I
with MMP-1 caused collagen type I to be degraded into
peptides of lower molecular sizes (Fig. 1A, compare lane 2
[nondigested control] vs. 4, 6, 8, and 10), and the b and c chain
bands of collagen type I to virtually disappear (a1 and a2
chains diminish more slowly). In contrast, after exposure to
RFUVA (Fig. 1A, compare lane 3 [nondigested control] vs. 5, 7,
9, and 11), the cross-linked collagen high-molecular-weight
polymers that are present at the c band position were not
degraded by MMP-1. As expected, the collagen at the a and b
band positions was reduced by incorporation into higher-
molecular-size polymers after exposure to RFUVA, but the
limited amounts of protein still remaining at those positions
did not appear to undergo digestion with MMP-1. When
collagen type I was exposed to three other MMPs (MMP-13, -2,
and -9), the a, b, and c chain bands of collagen type I were
significantly altered into lower-molecular-weight forms (Fig.
1B, C, and D, lane 1 [nondigested control] versus lanes 3, 5, 7,
and 9). In contrast, after exposure to RFUVA (Figs. 1B–D, lanes
2 [nondigested control] vs. 4, 6, 8, and 10), the cross-linked
collagen high-molecular-weight polymers that were present at
the c band position were not degraded by MMP-13 (Fig. 1B),
MMP-2 (Fig. 1C), or MMP-9 (Fig. 1D). Thus, collagen cross-
linked by RFUVA, especially that in the c band position, is
resistant to degradation by MMPs-1, -2, -9, and -13.
Data presented in Figure 2 represent the results of scanning
density analysis of SDS-PAGE bands with Image Quantity
software TL (GE Health Care Biosciences Corp.). The intensity
of c bands in RFUVA-treated collagen relative to the intensity of
c bands in nontreated control collagen as shown in Figure 1
was chosen as an indication of the ability of type I collagen to
resist degradation by MMP: when exposed to low concentra-
tions of MMPs (0.8 ng/lL), approximately 40% to 50% of non-
RFUVA–cross-linked control collagen remained resistant to
MMP-1 and -13, whereas approximately 10% resisted digestion
by MMP-2 and -9. When exposed to high concentrations of
MMPs (2 ng/lL), barely 10% of non-RFUVA–cross-linked
control collagen remained resistant after digestion by MMP-1,
-2, -9, or -13. In sharp contrast, however, prior exposure of
collagen to RFUVA caused most such cross-linked collagen to
be resistant to even the high concentration (2 ng/lL) of MMP-1
(80% resistant), MMP-13 (85%), MMP-2 (90%), or MMP-9 (70%).
To study the ability of MMPs to digest SLRPs, recombinant
SLRP core proteins, in the presence or absence of collagen
type I and with or without prior treatment with RFUVA, were
digested with MMP-1, MMP-2, MMP-9, and MMP-13, respec-
tively. In the cases of KER, LUM, MIM, DCN, and BGN, RFUVA
causes formation of polymers of a very wide range of MWs
from 100 and/or 150 kDa up to the bottom of the gel sample
well (Fig. 3A, lane 3 in each case). In the absence or presence
of soluble collagen, RFUVA causes cross-linking of all SLRPs,
thus forming polymers of a wide range of higher MWs, from
100 and/or 150 kDa up to the bottom of the gel sample well
(Fig. 3A, lane 4 in each case). Importantly, after incubation
with MMPs at a high concentration (2.0 ng/lL, as shown in Fig.
1), both the cross-linked SLRPs themselves (Fig. 3A, lane 3) and
also the mixture of SLRPs and collagen (Fig. 1, lane 4) appear
able to resist degradation. By quantitative analysis of the
amount of each SLRP remaining undigested at its normal gel
band position, as presented in Figure 3B, the results indicated
that most commercially available recombinant, nonglycosy-
lated SLRPs are not digested significantly by MMPs, as others
also have noted.45 This resistance to degradation by the four
most common corneal MMPs, in contrast to their readily
digestible behavior when treated with the same MMPs ex vivo
(see Fig. 5), may reflect the fact that these SLRPs have been
modified in three ways: (1) they have been modified greatly by
biosynthesis in nonglycosylated form, (2) they have undergone
modifications in amino acid sequence from wild type, and (3)
they have been modified by addition of covalent tags to allow
their solubility, even though they are very hydrophilic and
nonglycosylated (Table 2).
Whole corneas were treated ex vivo as described in
Materials and methods, either with saline (controls) or with
RFUVA, followed by extraction of all proteins, treatment or not
with MMPs, and analysis by Western blotting. Figure 4 shows
Western blots of the electrophoretic migration pattern of the a,
b, and c component molecules of collagen types I and IV
extracted from whole corneas ex vivo, nontreated controls
versus cross-linked by RFUVA, after extraction with GHCl, and
then digestion with MMPs-1, -13, -2, or -9. Digestion of
extracted samples with MMP-1 (Fig. 4A) caused nontreated
control collagen type I (Fig. 4A, lane 1) to generate a series of
low-MW peptides and caused the disappearance of a chains, b
chains, and c chains (Fig. 4A, MMP-1 digestion: lanes 3, 5, 7,
and 9). Conversely, corneas exposed ex vivo to RFUVA prior to
extraction with GHCl yielded collagens that showed staining
intensity of c chains, and the cross-linked collagen polymers at
the high-MW range remained unchanged by digestion with 0.4
to 1.6 ng/lL concentrations of MMP-1, with no new bands of
low-MW peptides observed (Fig. 4A, nondigested controls, lane
2 versus MMP-digested, lanes 4, 6, 8, and 10). A similar result
was obtained after digestion of extracted samples with MMP-13
and Western blotting with antibodies for type I collagen (Fig.
4B). In addition, samples extracted from control corneas and
corneas exposed ex vivo to RFUVA alternatively were digested
with MMP-2, separated by SDS-PAGE and subjected to Western
blotting with antibodies to collagen type IV (Fig. 4C, non-
treated controls [lane 1]) versus digestion with 0.4 to 1.6 ng/lL
concentrations of MMP-2: lanes 3, 5, 7, and 9. Results indicated
that type IV collagen in samples extracted from control
corneas underwent degradation by MMP-2 to a range of
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lower-MW bands whose density increased at higher enzyme
concentrations. In sharp contrast, however, prior treatment of
the cornea ex vivo with RFUVA generated patterns of cross-
linked higher-MW polymers of type IV collagen that were not
affected by digestion with MMP-2. A similar result also was
observed when samples from control and RFUVA-treated ex
vivo corneas were digested with MMP-9 and then analyzed by
Western blotting with antibodies for type IV collagen (Fig. 4D).
Thus, these results indicate that collagen types I and IV in
nontreated control corneas ex vivo upon extraction and
incubation with MMPs, are degraded to lower MW forms,
generally to a ‘‘terminal digest’’ array of peptides whose
concentrations are more prominent with use of higher MMP
concentrations. In sharp contrast, samples extracted from
corneas that had been exposed ex vivo to RFUVA upon
incubation with MMPs show high-MW patterns of collagen
types I and type IV cross-linked by RFUVA that resist cleavage
by MMPs.
Relative susceptibility of the most common corneal SLRP
proteins to digestion by MMPs before and after RFUVA cross-
linking was described in Figure 3. However, those analyses
were performed with commercially available and slightly
modified (Table 2) purified recombinant nonglycosylated
proteins in solution in vitro. In the natural environment of
the cornea, those proteins would each carry at least one
covalently bound chain of sulfated GAG, providing a degree of
solubility sufficient to allow their exocytosis and diffusion
within the extracellular matrix (whereas such normal core
proteins, very hydrophilic and lacking such glycosylation, are
insoluble). In addition, the core proteins of such native
proteoglycan molecules are thought to normally wrap their
hydrophobic domains around polymerized collagen fibrils,
thus potentially presenting a conformation quite distinct from
that of the nonglycosylated, artificially tagged (Table 2),
purified recombinant proteins in solution used in Figure 3.
To determine the susceptibility of normal, glycosylated core
SLRPs to MMPs before or after RFUVA treatment of whole
corneas ex vivo, as described in Materials and Methods, RFUVA-
treated and nontreated whole corneas were extracted with
GHCl and the harvested macromolecules were incubated with
or without MMP-1. Figures 5A, 5B, 5C, 5D, and 5E display the
Western blot profiles of the main SLRPs extracted from such
FIGURE 1. Type I collagen (from bovine skin, commercially obtained), control, and RFUVA–cross-linked, digested with MMPs. SDS polyacrylamide
gels stained with Coomassie Blue. (A) (1) Compared to the nondigested control (lanes 2 and 3), cross-linked collagen in the gel well bottom was not
digested by MMP-1 (lanes 5, 7, 9, and 11). (2) Similarly, cross-linked collagen in the c band position was not digested by MMP-1 (nondigested control
[lanes 2 and 3] versus lanes 5, 7, 9, and 11). (3). Native collagen (nondigested control lane 2), when exposed to a range of concentrations of MMP-1
generated a range of lower molecular size peptides (lanes 4, 6, 8, and 10). However, samples that had undergone RFUVA cross-linking generated no
new lower-weight-molecular bands upon exposure to MMP-1 (nondigested, RFUVA-treated control: lane 3 versus lanes 5, 7, 9, and 11). Similar
results were observed with MMP-13 (B), MMP-2 (C), and MMP-9 (D).
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corneas incubated with or without MMP-1. Comparison of
sample lanes 1 (nontreated control) in Figures 5A, 5B, 5C, 5D,
and 5E versus lane 3 (MMP-digested). Figures 5A, 5B, 5C, 5D,
and 5E indicates that each such control SLRP was cleaved by
MMP-1, generating at least one peptide of lower-MW (note, the
normal, glycosylated core proteins in Figs. 5A–E, lane 1, exist
in a range of MWs, thus generating a diffuse smear of higher-
MW antibody-positive staining, rather than the single band of
core proteins in their nonglycosylated forms seen in Fig. 3).
Staining patterns in lane 3 in Figures 5A, 5B, 5C, 5D, and 5E
include at least one distinct band of lower-MW, probably a
nonglycosylated peptide fragment, visibly indicating significant
digestion of each of the four core SLRPs by MMP-1. In contrast,
after exposure of whole corneas to RFUVA, followed by
extraction of macromolecules with GHCl, RFUVA cross-linking
between core proteins and other proteins generates a range of
higher-MW polymers (Figs. 5A–E, lane 2). Importantly, when
such samples from RFUVA-treated corneas are incubated with
TABLE 1. Amino Acid Analysis of Native and Treated Collagen with RFUVA
Amino Acid
Collagen Type I Collagen Type IV
Untreated RFUVA Treated Untreated RFUVA Treated
Hyp 9.43 6 0.05 9.27 6 0.05 11.04 6 0.04 10.2 6 0.06
Asp 4.7 6 0.04 4.74 6 0.01 5.16 6 0.02 5.3 6 0.05
Thr 1.54 6 0.06 1.59 6 0.01 2.38 6 0.03 2.44 6 0.05
Ser 3.16 6 0.03 3.08 6 0.05 3.96 6 0.02 4.34 6 0.17
Glu 7.07 6 0.03 7.34 6 0.06 8.55 6 0.06 8.56 6 0.03
Pro 12.75 6 0.03 12.76 6 0.05 8.13 6 0.03 8.46 6 0.25
Gly 33.92 6 0.09 34.69 6 0.11 31.56 6 0.08 32.29 6 0.46
Ala 10.32 6 0.21 10.86 6 0.05 3.55 6 0.02 4.25 6 0.02
Val 1.97 6 0.03 1.91 6 0.08 2.86 6 0.01 2.84 6 0.02
Met 0.58 6 0.01 0.23 6 0.07 1.22 6 0.01 0.74 6 0.05
Ile 1.21 6 0.01 1.19 6 0.01 3.24 6 0.01 3.16 6 0.03
Leu 2.3 6 0.02 2.32 6 0.04 5.24 6 0.02 5.08 6 0.02
Tyr 0.62 6 0.01 0.32 6 0.01 0.88 6 0.03 0.53 6 0.08
Phe 1.23 6 0.02 1.3 6 0.01 2.81 6 0.04 2.52 6 0.06
His 0.44 6 0.01 0.16 6 0.01 0.66 6 0.02 0.21 6 0.05
Hlys 0.67 6 0.02 0.54 6 0.02 4.66 6 0.13 4.7 6 0.03
Lys 2.74 6 0.04 2.65 6 0.24 0.83 6 0.02 0.73 6 0.03
Arg 5.23 6 0.03 5.17 6 0.03 3.28 6 0.12 3.32 6 0.02
Collagen (1 lg/lL in PBS) and RF (0.1% in PBS) was irradiated with UVA at 370 nm for 30 minutes at a distance of 5 cm from the light source at
room temperature. Molar ratio (%) was represented by the molar concentration of each amino acid per total amino acids. Data are means6 SD from
three separate experiments.
FIGURE 2. Quantitative analysis of the resistance of collagen type I to degradation by MMPs before and after RFUVA cross-linking. (A) MMP-1; (B)
MMP-13; (C) MMP-2; (D) MMP-9. Data are percentages of the c band remaining (resistant) in experimental samples after digestion with MMPs
compared to the c band from nontreated native control collagen.
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MMP-1, lower MW forms are not generated (Figs. 5A–E, lane 4),
indicating that RFUVA treatment of corneas ex vivo cross-links
SLRPs to one another and possibly to other proteins, too, and
allows them to resist degradation by MMP-1.
Finally, as an independent approach to determining the
response of native, glycosylated SLRPs in vivo before and after
RFUVA treatment to digestion with MMPs, Figure 6 shows the
patterns of KS chains and CS chains attached to SLRPs.
Irradiation of whole corneas ex vivo with RFUVA causes SLRPs
bearing KS chains or CS chains to migrate near the top of the
gel (Figs. 6A, 6B, lane 2; in the same locations that antibodies to
the SLRPs themselves were seen in Fig. 5, lane 2). Here, the
locations of the KS and CS chains are used simply to reveal the
locations of the SLRPs to which they are natively covalently
bound, compared with that of the control samples in the
absence of RFUVA (Figs. 6A, 6B, lane 1). It is noteworthy that
previous work has indicated that RFUVA does not crosslink the
GAG chains,42 per se, but their presence on most of the SLRP
FIGURE 3. Effects of incubating SLRPs with MMPs. (A) Western blot analysis of the behaviors of core proteins in the absence or presence of
collagen, then treated or not with RFUVA, and finally incubated with MMPs. (B) Quantitative analysis of the amount of each core protein remaining
(resistant) after incubation with (lane[s] 2, above) or without (lane[s] 1, above) MMPs in the absence of collagen and in the absence of RFUVA
treatment, as assessed by measurements of band intensities (performed in triplicate).
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FIGURE 4. Western blot analysis of collagens I and IV in samples extracted from corneas treated ex vivo: control versus RFUVA–cross-linked,
extracted with GHCl and then digested with MMPs. Extracted samples were treated with MMPs, then separated by gel electrophoresis, and
subjected to Western blot analysis with antibodies specific to collagens I or IV (in each case, lanes 1 and 2 were not digested with MMPs,
nondigested controls). (A) Treated with MMP-1, antibody to collagen type I. (B) Treated with MMP-13, antibody to collagen type I. (C) Treated with
MMP-2, antibody to collagen type IV. (D) Treated with MMP-9, antibody to collagen type IV. (A–D) Compared to samples extracted from untreated
control corneas (lane1), which displayed susceptibility to digestion with all MMPs tested here (lanes 3, 5, 7, and 9), samples extracted from RFUVA–
cross-linked corneas (lane 2) exhibited resistance to MMP degradation (lanes 4, 6, 8, and 10).
FIGURE 5. Migration of native PGs extracted from control and RFUVA–cross-linked ex vivo corneas, then subsequently digested with MMP-1.
Detection of their SLRP core proteins via Western blotting with antibodies specific to each of the following SLRPs: (A) keratocan; (B) lumican; (C)
mimecan; (D) decorin; and (E) biglycan. Compared to untreated samples (lane 1), all five PG core proteins as normally glycosylated corneal PGs, as
a broad range of MWs, undergo digestion, generating at least one significant peptide of lower-MW upon incubation with MMP-1 (lane 3). In sharp
contrast, corneal PGs extracted from corneas that had undergone RFUVA cross-linking migrated as a range of high-MW molecules, even after
incubation with MMP-1, thus indicating that exposure of whole corneas to RFUVA generates cross-linked proteoglycan SLRP core proteins that can
resist degradation by MMP-1.
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core proteins, together with other potential sites of glycosyl-
ation, collectively generate PG molecules with a range of MWs
(Figs. 6A, 6B, lane 1). In response to treatment with MMP-1, the
intensity levels of KS and CS in control samples sharply
decreased or disappeared (Figs. 6A, 6B, lane 3) because
digestion of their attached core proteins released peptide
fragments carrying the GAG chains, which thereafter were
likely washed out of the gels following SDS-PAGE. However, in
samples extracted from RFUVA-treated corneas, significant
reactivity of KS and CS is detected in the same high MW region
for RFUVA-treated samples treated with MMP-1 (Figs. 6A, 6B,
lane 4) as for their respective nondigested controls (Figs. 6A,
6B, lane 1). This indicates that the core SLRP to which they are
natively attached remain cross-linked to one another (as shown
in Fig. 5) and to other proteins, and remain intact even after
incubation with MMP-1, as revealed by the location of their
GAG chain prosthetic groups. Thus, the presence of KS and CS
chains occurs in the same high-MW regions of the same
samples those probed for the presence of the core SLRP (Fig. 5,
lanes 2 and 4). These results, significantly, indicate that RFUVA
treatment of whole corneas not only effectively cross-links
collagens and SLRP core proteins and renders them resistant to
degradation by MMPs, but also immobilizes the posttransla-
tional modifications attached to them, in this case, the KS and
CS chains, which by themselves do not participate in RFUVA-
induced cross-linking.
DISCUSSION
In the cornea, collagen cross-linking occurs naturally with aging
due to an oxidative deamination reaction that takes place within
the end chains of the collagen.46,47 Keratoconus is generally first
diagnosed in young people at puberty or in their late teens,
progresses for 10 to 20 years, and then slows or stabilizes by
approximately the age of 40.48 Irradiation of the cornea with
UVA in the presence of RF40,41 effectively stops the progression
of keratoconus, although the mechanism by which RFUVA cross-
linking stops it remains to be demonstrated.
In this study, we used both an in vitro and an ex vivo model
reaction system to investigate the effects of RFUVA cross-linking
of collagens and SLRPs on their ability to resist enzymatic
digestion by MMPs, an interaction very likely to occur following
clinical corneal cross-linking. Data presented in Table 1 indicate
the changes in molar percentage of amino acids that are
detected before and after RFUVA cross-linking of collagen types
I and IV. Compared to native collagens, RFUVA causes distinct
decreases in molar percentages of Met, Tyr, His, Hlys, and Lys in
cross-linked collagens, suggesting that these amino acids are
modified by RFUVA, just as they are as free amino acids in
solution, with the latter being very susceptible to photodegra-
dation in the presence of RFUVA.49 During corneal RFUVA
cross-linking treatment, RF is a key component as it is excited
by UVA into its triplet state, generating singlet oxygen that can
react further with various molecules,41 inducing chemical
bonds to form that covalently link amino groups of collagen
fibrils50 with those of other proteins in the corneal stroma
extracellular matrix.42 These reactions may involve tyrosine
residues,51 advanced glycation end products, 50,52 or changes in
secondary or tertiary structure.53,54 Tyrosine residues in the
terminal, telopeptide domains of collagen alpha chains can
form pi-pi complexes,55 leading to dityrosine cross-links.56–59
Histidine residues in collagen may produce cross-links in the
presence of singlet oxygen.60 Methionine residues in collagen
fibrils may be involved in RFUVA cross-linking as indicated by
changes in the patterns of CNBr cleavage products.42 In
addition, irradiation of RFUVA can induce lysine to form
glycosyl-lysine cross-links (Maillard reaction) and so-called
advanced glycation end products (AGEs),40,52 suggesting that
corneal cross-linking is carbonyl-dependent and involves the
formation of AGE cross-links.41,50 RFUVA thus causes apparent
disappearance of tyrosine, histidine, methionine, and lysine/
TABLE 2. Molecular Modifications of Recombinant Human SLRPs from Wild-Type Sequences, To Foster Their Solubility as Non-Glycosylated
Proteins
Recombinant
Human SLRP
Molecular
Mass,
kDa Location of Modification Commercial Source
Keratocan 36.63 Partial 253AA–351AA, with GST tag at the N terminus Abnova Corp.
Lumican 37.5 Mouse myeloma cell line NS0-derived Gln19–Asn338, with a C-terminal 6-His tag R&D Systems
Mimecan 32.6 Mouse myeloma cell line NS0-derived Ala20–Phe298, with a C-terminal 6-His tag R&D Systems
Decorin 38 Spodoptera frugiperda Sf21(baculovirus)-derived Gly17–Lys359, with a C-terminal 6-His tag R&D Systems
Biglycan 37.5 Mouse myeloma cell line NS0-derived Asp38–Lys368, with a C-terminal 6-His tag R&D Systems
FIGURE 6. Migration of native PGs extracted from control and RFUVA–
cross-linked ex vivo corneas, then subsequently digested with MMP-1.
Locations of the PG core protein SLRPs are revealed by detection of
their covalently attached GAGs. (A) Western blots using antibody for
KS. (B) Western blots using antibody for CS. Compared to untreated
samples (lane 1), the core SLRPs, which are natively covalently
attached to KS or CS GAG chains in normal corneal PGs, undergo
digestion to lower-MW forms upon incubation with MMP-1 (lane 3),
carrying with them into consequent disappearance the attached GAG
chains. In sharp contrast, corneal PGs extracted from corneas that had
undergone RFUVA cross-linking, migrated as a range of high-MW
molecules, even after incubation with MMP-1, thus indicating that
exposure of whole corneas to RFUVA generates cross-linked PGs
whose core proteins can resist degradation by MMP-1 and thus can
retain their covalently attached GAG chains (lane 4), even though such
GAG chains do not participate in RFUVA covalent cross-linking per se.
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hydroxylysine while concomitantly converting their structures
while still in peptide linkage to participate in covalent cross-
links (which are not detected during normal amino acid
analyses) (Table 1).
Preventing protein degradation by MMPs is an essential goal
in the clinical efficacy of the cross-linking treatment for
keratoconus because already demonstrated increased MMPs
activity is one of the most important factors causing corneal
thinning. The stroma comprises approximately 90% of the
cornea thickness in humans.5 Collagen gives the cornea its
strength, elasticity, and form.6 Type I collagen, the most
abundant collagen in corneal stroma,10 is composed of three
polypeptide chains: two types of single chains, a1 and a 2, both
of which are accessible to polymerization through intra- and
intermolecular bonds.61 Dimers of a chains are called b
components (composed of a1-a2 or a1-a1 chains). Trimers of
three a chains are called c components. The strength of the
collagen fibers depends on the formation of covalent cross-links
between the N and C termini, nonhelical telopeptide domains,
and adjacent helical domains of collagen molecules.62 RF-
sensitized photodynamic modification of collagen causes
formation of cross-linked molecules in which an energy transfer
between the excited RF and molecular oxygen produces singlet
oxygen that then interacts with the collagen fibrils in an
oxidation reaction to form physical, covalent cross-links.52
Previous studies demonstrated that RFUVA mainly causes
a1, a2, b11, and b12 chains to cross-link into macromolecules
at least as large and larger than c components, including those
trapped at the bottom of sample wells, and thus disappear
from their normal a-, and b-chain positions on electrophoretic
gels.42,44 Intermicrofibrillar cross-links significantly affect the
mechanical properties of corneal collagen tissue.63 Earlier
studies showed that RFUVA–cross-linked intact rabbit corneal
tissues can resist digestion by bacterial collagenase.64,65
However, effects of RFUVA on resistance of collagen fibrils
and PG core proteins to digestion by corneal endogenous
MMPs remained lacking. Our data presented here clearly
demonstrate that the initial c band of collagen type I in the
absence of RFUVA (Fig. 1) is distinctly digested by MMPs,
whereas the new c-components formed by RFUVA are very
resistant to digestion. For the stabilizing property of cross-
linked collagen, one possible explanation may be the changes
of the tertiary structure to prevent MMPs access to their
specific cleavage sites by steric hindrance.66,67 In addition, it is
likely that some of the normal MMP cleavage sites within the
collagen fibrils may be blocked during the RFUVA cross-linking,
thus forming new high-molecular-weight polymers, as ob-
served at the c band position and the bottom of the sample
wells (Fig. 1), suggesting that the MMPs cleavage sites may be
modified by RFUVA cross-linking. In addition, data presented in
Figure 2 show that non–cross-linked control type I collagen
appears more susceptible to digestion by MMP-2 and MMP-9
than to that by MMP-1 or MMP-13, whereas RFUVA–cross-
linked collagen appears totally resistant to MMP-13 and highly
resistant to MMP-1, -2, and -9.
Data presented in Figure 3 reveal that the presence of
soluble collagen during RFUVA does not increase the
subsequent digestion of soluble, commercial, recombinant,
nonglycosylated, chemically tagged (Table 2) SLRPs by MMPs.
Thus, in both non-RFUVA–cross-linked and RFUVA–cross-linked
form, such SLRPs are mostly resistant to digestion by the four
most common SLRPs of the cornea, whereas in sharp contrast,
they are quite digestible by those same MMPs when the SLRPs
are available ex vivo in their normal glycosylated forms and
bound to fibrillar collagen. In cornea and in other tissues, any
of these core proteins may exist either in forms lacking
glycosylation or with glycosylation consisting of GAGs chains
of various lengths. Such PG core proteins, even when heavily
glycosylated with GAG chains, are modeled as binding with
their leucine-rich domains directly to the sides of collagen
fibrils.68,69 The narrow collagen fibrils of corneal stroma
associate with the core SLRPs of the PGs, whose sulfated
GAG chains appear as variable-length linear structures extend-
ing laterally from the collagen fibrils.70 Considering these
structural models, our data show that RFUVA causes PG core
proteins to crosslink themselves, blocking the MMPs cleavage
sites as effectively in the absence or presence of soluble
collagen, leading core proteins to form high-MW copolymers
(Fig. 3A, lane 4). In addition, the covalent cross-linking
between PG core proteins and collagen induced by RFUVA
may result in saturation of the MMPs cleavages sites on
collagen fibrils.42 The ability of cross-linked PG core proteins to
protect collagen fibrils from catabolism by MMPs provides an
additional potential effect of the interaction of SLRPs and
collagen. Moreover, data presented in Figure 3B also suggested
that nonglycosylated, commercially modified SLRPs, although
mostly resistant to all 4 MMPs, appear to be digested by MMP-13
and MMP-9 somewhat more easily than by MMP-2 and MMP-1.
Soluble commercial, recombinant, nonglycosylated chemi-
cally tagged (Table 2) SLRPs generally were resistant to
digestion with the four most common corneal MMPs (Figs.
3A, 3B), whereas those same core SLRPs were readily digested
by those same MMPs when exposed to them after their
extraction in their native glycosylated forms from whole
corneas ex vivo. We propose three possible explanations for
this contrast in sensitivity of these SLRPs to degradation by
MMPs: (1) the commercial changes made in the recombinant
versions of the SLRP proteins (to make them soluble) (Table 2)
may render them mostly resistant to digestion by corneal
MMPs; (2) glycosylation of SLRPs , generally with GAG chains
of KS or CS, changes their conformation, allowing them to
become digestible by MMPs; and/or (3) normal binding of the
glycosylated SLRPs to their binding partners in vivo (e.g.,
collagen fibrils) allows them to become digestible by MMPs.
Using native PGs extracted from corneas ex vivo, MMPs are
able to digest SLRP core proteins. However, after treatment
with RFUVA, cross-links form between those proteins in such a
manner that they become much more resistant to digestion,
even in the presence of soluble collagen, by the normal
extracellular degradative enzymes of the corneal stroma, the
MMPs, as demonstrated in this study.
The ECM of normal corneas becomes more cross-linked
and insoluble during normal aging, and RFUVA treatment of
the cornea (including the already-insoluble ECM mass that
has slowly formed there) adds additional covalent cross-links
within that mass between proteins already there and adds
more proteins to it. In this study, 4 M GHCl was used to
extract the soluble molecules of the corneal stroma from
both normal control and RFUVA–cross-linked bovine corneas
ex vivo. As a classical method for protein extraction, 4 M
GHCl has been widely used to isolate PGs43,71 and also
extract collagens from corneal tissues.72,73 In this type of
extraction, noncovalent intra- and intermolecular bonds
between macromolecules are broken, and the corneal
aggregate structure is dissociated into its soluble compo-
nents.74 Our results demonstrated that GHCl extraction was
an effective method for isolation of partially cross-linked
collagens and PGs from normal control corneas, and from
RFUVA–cross-linked bovine corneas, although the recovery
of total PGs and collagen is incomplete. However, more
details of molecular cross-linking could be found by studying
the insoluble aggregated ECM of normal and RFUVA corneas
and their responses to MMPs. Nonetheless, the cross-linking
process can still be studied profitably in this representative,
soluble portion of the stromal ECM.
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Evidence presented in Figure 4 indicates that corneal
collagen types I and IV, examined here after undergoing
RFUVA cross-linking ex vivo followed by extraction with GHCl,
both display resistance to degradation by MMPs. Collagen type
IV is a primary component of corneal epithelial basement
membranes, a structure important for corneal functions and
cell adhesion.75 Disrupted distribution of type IV collagen was
noted in the basement membrane of the keratoconic cor-
neas.76,77 Basement membrane alterations may interfere with
critical interactions of the corneal epithelium with the
underlying basement membrane, as well as cell-matrix
interactions and matrix organization in the stroma.78 Interest-
ingly, our data demonstrated that RFUVA–cross-linked collagen
type IV can resist degradation by MMP-2 and MMP-9,
suggesting that further damage to the corneal basement
membrane of keratoconus may be halted by RFUVA treatment.
In the present study, we also examined the responses of ex
vivo native and RFUVA–cross-linked PG core proteins to
digestion with MMPs. Our recent work demonstrated that
RFUVA causes linkages between collagens and PG core
proteins both in vitro and ex vivo.42 Here, we demonstrate
that RFUVA–cross-linked PG core proteins display resistance to
digestion with MMP-1 (Fig. 5). Moreover, data presented in
Figure 6 reveal that the normal GAG chains, KS and CS, natively
attached to PG core proteins, disappear along with the remains
of their linkage region peptides upon digestion of non-RFUVA–
cross-linked corneal stroma with MMPs. However, they remain
intact, still attached to their nondigested core proteins after
RFUVA cross-linking. Thus, complete, native PGs glycosylated
with attached GAG chains in the corneal stroma are susceptible
to degradation by MMPs, but become resistant to degradation
in response to RFUVA treatment either in vitro solution or in
native corneal stromal matrix ex vivo.
In summary, this work presents a novel approach for
understanding the mechanism by which RFUVA cross-linking
appears to stop the progression of keratoconus. Our results
strikingly demonstrate that corneal RFUVA–cross-linked colla-
gen and PG core proteins can resist cleavage by MMPs.
Moreover, it is likely that the formation of covalent cross-links
between collagen and SLRPs induced by RFUVA contributes
added protection to collagen fibrils from degradation by MMPs.
The ability of MMPs to digest several other corneal ECM
proteins before and after RFUVA cross-linking in solution in
vitro versus ex vivo (e.g., collagen types I with V and collagen
type IV with laminin, fibronectin, and fibrillin) remain to be
characterized.
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